ARL4C and prostate adenocarcinoma: Specifically, ARL4C expression was lower in ACC, breast cancer (BRCA), KICH, prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), and thyroid carcinoma (THCA) compared to normal tissues.